Drug Profile
Pegaspargase biosimilar - Amega Biotech
Alternative Names: PEG-asparaginase biosimilar - Amega BiotechLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Amega Biotech
- Class Amidohydrolases; Antineoplastics; Polyethylene glycols
- Mechanism of Action Aspartate-ammonia ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 15 Aug 2013 Investigation in Acute lymphoblastic leukaemia in Argentina (Parenteral)